Nurix Therapeutics, Inc. (NRIX)
25.10
-0.71
(-2.75%)
USD |
NASDAQ |
Sep 11, 16:00
25.01
-0.09
(-0.36%)
After-Hours: 06:35
Nurix Therapeutics Max Drawdown (5Y) : 91.53% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 91.53% |
| July 31, 2026 | 91.53% |
| June 30, 2026 | 91.53% |
| May 31, 2026 | 91.53% |
| April 30, 2026 | 91.53% |
| March 31, 2026 | 91.53% |
| February 28, 2026 | 91.53% |
| January 31, 2026 | 91.53% |
| December 31, 2025 | 91.53% |
| November 30, 2025 | 91.53% |
| October 31, 2025 | 91.53% |
| September 30, 2025 | 91.53% |
| August 31, 2025 | 91.53% |
| July 31, 2025 | 91.53% |
| June 30, 2025 | 91.53% |
| May 31, 2025 | 91.53% |
| April 30, 2025 | 91.53% |
| March 31, 2025 | 91.53% |
| February 28, 2025 | 91.53% |
| January 31, 2025 | 91.53% |
| December 31, 2024 | 91.53% |
| November 30, 2024 | 91.53% |
| October 31, 2024 | 91.53% |
| September 30, 2024 | 91.53% |
| August 31, 2024 | 91.53% |
| Date | Value |
|---|---|
| July 31, 2024 | 91.53% |
| June 30, 2024 | 91.53% |
| May 31, 2024 | 91.53% |
| April 30, 2024 | 91.53% |
| March 31, 2024 | 91.53% |
| February 29, 2024 | 91.53% |
| January 31, 2024 | 91.53% |
| December 31, 2023 | 91.53% |
| November 30, 2023 | 91.53% |
| October 31, 2023 | 91.53% |
| September 30, 2023 | 84.33% |
| August 31, 2023 | 84.29% |
| July 31, 2023 | 84.29% |
| June 30, 2023 | 84.29% |
| May 31, 2023 | 84.29% |
| April 30, 2023 | 84.29% |
| March 31, 2023 | 84.29% |
| February 28, 2023 | 84.29% |
| January 31, 2023 | 84.29% |
| December 31, 2022 | 84.29% |
| November 30, 2022 | 84.29% |
| October 31, 2022 | 84.29% |
| September 30, 2022 | 84.29% |
| August 31, 2022 | 84.29% |
| July 31, 2022 | 84.29% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Cue Biopharma, Inc. | 99.01% |
| Keros Therapeutics, Inc. | 88.46% |
| Monte Rosa Therapeutics, Inc. | 94.08% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -24.40 |
| Beta (5Y) | 1.801 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 74.50% |
| Historical Sharpe Ratio (5Y) | -0.1082 |
| Historical Sortino (5Y) | -0.2344 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 28.11% |